Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
Identifieur interne : 000071 ( Main/Exploration ); précédent : 000070; suivant : 000072Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
Auteurs : Bernard I. Lévy [France] ; Jean-Pierre Fauvel [France]Source :
- Archives of cardiovascular diseases [ 1875-2128 ]
Descripteurs français
- KwdFr :
- Antagonistes du récepteur de type 1 de l'angiotensine-II (usage thérapeutique), Betacoronavirus (MeSH), Humains (MeSH), Infections à coronavirus (métabolisme), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Pandémies (MeSH), Pneumopathie virale (métabolisme), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Système rénine-angiotensine (effets des médicaments et des substances chimiques).
- MESH :
- effets des médicaments et des substances chimiques : Système rénine-angiotensine.
- métabolisme : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antagonistes du récepteur de type 1 de l'angiotensine-II, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Humains, Pandémies.
English descriptors
- KwdEn :
- Angiotensin II Type 1 Receptor Blockers (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (metabolism), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (metabolism), Renin-Angiotensin System (drug effects).
- MESH :
- chemical , therapeutic use : Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors.
- drug effects : Renin-Angiotensin System.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Humans, Pandemics.
Abstract
Severe acute respiratory syndrome coronavirus 2, which is responsible for the current coronavirus disease 2019 pandemic, uses angiotensin-converting enzyme 2 as a gateway into host cells. In this review, we summarise the biology of this enzyme, which plays a key role in cardiovascular homeostasis. Blockers of the renin-angiotensin system modify the expression and activity of angiotensin-converting enzyme 2 in different ways. The effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the expression and enzyme activity of angiotensin-converting enzyme 2 are reviewed, and the consequences of these treatments for the severity of coronavirus disease 2019 infection are discussed.
DOI: 10.1016/j.acvd.2020.07.001
PubMed: 32863157
PubMed Central: PMC7430243
Affiliations:
- France
- Auvergne-Rhône-Alpes, Rhône-Alpes, Île-de-France
- Lyon, Paris
- Université Claude Bernard Lyon 1
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.</title><author><name sortKey="Levy, Bernard I" sort="Levy, Bernard I" uniqKey="Levy B" first="Bernard I" last="Lévy">Bernard I. Lévy</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR970 (PARCC) and Hôpital Lariboisière, 75010 Paris, France. Electronic address: bernard.levy@inserm.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR970 (PARCC) and Hôpital Lariboisière, 75010 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Fauvel, Jean Pierre" sort="Fauvel, Jean Pierre" uniqKey="Fauvel J" first="Jean-Pierre" last="Fauvel">Jean-Pierre Fauvel</name><affiliation wicri:level="4"><nlm:affiliation>Service de Néphrologie, UMR 5558, Université Claude Bernard Lyon 1, Hôpital Édouard-Herriot, Hospices Civils de Lyon, 69437 Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Néphrologie, UMR 5558, Université Claude Bernard Lyon 1, Hôpital Édouard-Herriot, Hospices Civils de Lyon, 69437 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Aug - Sep</date><idno type="RBID">pubmed:32863157</idno><idno type="pmid">32863157</idno><idno type="doi">10.1016/j.acvd.2020.07.001</idno><idno type="pmc">PMC7430243</idno><idno type="wicri:Area/Main/Corpus">000298</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000298</idno><idno type="wicri:Area/Main/Curation">000298</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000298</idno><idno type="wicri:Area/Main/Exploration">000298</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.</title><author><name sortKey="Levy, Bernard I" sort="Levy, Bernard I" uniqKey="Levy B" first="Bernard I" last="Lévy">Bernard I. Lévy</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR970 (PARCC) and Hôpital Lariboisière, 75010 Paris, France. Electronic address: bernard.levy@inserm.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR970 (PARCC) and Hôpital Lariboisière, 75010 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Fauvel, Jean Pierre" sort="Fauvel, Jean Pierre" uniqKey="Fauvel J" first="Jean-Pierre" last="Fauvel">Jean-Pierre Fauvel</name><affiliation wicri:level="4"><nlm:affiliation>Service de Néphrologie, UMR 5558, Université Claude Bernard Lyon 1, Hôpital Édouard-Herriot, Hospices Civils de Lyon, 69437 Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Néphrologie, UMR 5558, Université Claude Bernard Lyon 1, Hôpital Édouard-Herriot, Hospices Civils de Lyon, 69437 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author></analytic><series><title level="j">Archives of cardiovascular diseases</title><idno type="eISSN">1875-2128</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin II Type 1 Receptor Blockers (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (metabolism)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (metabolism)</term><term>Renin-Angiotensin System (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes du récepteur de type 1 de l'angiotensine-II (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Système rénine-angiotensine (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin II Type 1 Receptor Blockers</term><term>Angiotensin-Converting Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Renin-Angiotensin System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Système rénine-angiotensine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes du récepteur de type 1 de l'angiotensine-II</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus 2, which is responsible for the current coronavirus disease 2019 pandemic, uses angiotensin-converting enzyme 2 as a gateway into host cells. In this review, we summarise the biology of this enzyme, which plays a key role in cardiovascular homeostasis. Blockers of the renin-angiotensin system modify the expression and activity of angiotensin-converting enzyme 2 in different ways. The effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the expression and enzyme activity of angiotensin-converting enzyme 2 are reviewed, and the consequences of these treatments for the severity of coronavirus disease 2019 infection are discussed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32863157</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-2128</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>8-9</Issue><PubDate><MedlineDate>2020 Aug - Sep</MedlineDate></PubDate></JournalIssue><Title>Archives of cardiovascular diseases</Title><ISOAbbreviation>Arch Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.</ArticleTitle><Pagination><MedlinePgn>572-578</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1875-2136(20)30157-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acvd.2020.07.001</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2, which is responsible for the current coronavirus disease 2019 pandemic, uses angiotensin-converting enzyme 2 as a gateway into host cells. In this review, we summarise the biology of this enzyme, which plays a key role in cardiovascular homeostasis. Blockers of the renin-angiotensin system modify the expression and activity of angiotensin-converting enzyme 2 in different ways. The effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the expression and enzyme activity of angiotensin-converting enzyme 2 are reviewed, and the consequences of these treatments for the severity of coronavirus disease 2019 infection are discussed.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lévy</LastName><ForeName>Bernard I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Inserm UMR970 (PARCC) and Hôpital Lariboisière, 75010 Paris, France. Electronic address: bernard.levy@inserm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauvel</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Service de Néphrologie, UMR 5558, Université Claude Bernard Lyon 1, Hôpital Édouard-Herriot, Hospices Civils de Lyon, 69437 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Société Française d’Hypertension Artérielle</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Arch Cardiovasc Dis</MedlineTA><NlmUniqueID>101465655</NlmUniqueID><ISSNLinking>1875-2128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin receptor blockers</Keyword><Keyword MajorTopicYN="N">Angiotensin-converting enzyme inhibitors</Keyword><Keyword MajorTopicYN="N">Arterial hypertension</Keyword><Keyword MajorTopicYN="N">Bloqueur des récepteurs de l’angiotensine</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Hypertension artérielle</Keyword><Keyword MajorTopicYN="N">Inhibiteurs de l’enzyme de conversion de l’angiotensine</Keyword><Keyword MajorTopicYN="N">Insuffisance cardiaque</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32863157</ArticleId><ArticleId IdType="pii">S1875-2136(20)30157-1</ArticleId><ArticleId IdType="doi">10.1016/j.acvd.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7430243</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Lyon</li><li>Paris</li></settlement><orgName><li>Université Claude Bernard Lyon 1</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Levy, Bernard I" sort="Levy, Bernard I" uniqKey="Levy B" first="Bernard I" last="Lévy">Bernard I. Lévy</name></region><name sortKey="Fauvel, Jean Pierre" sort="Fauvel, Jean Pierre" uniqKey="Fauvel J" first="Jean-Pierre" last="Fauvel">Jean-Pierre Fauvel</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000071 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000071 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32863157
|texte= Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32863157" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |